Song Soo Kim (Chungnam National University Hospital)
● Authors
Song Soo Kim,David A. Lynch2,Eric Yow3,Kevin Flaherty4,MeiLan K. Han3
● Affiliation
Chungnam National University Hospital1,National Jewish Health, University of Colorado Denver School of Medicine2,University of Michigan Health System3,University of Michigan, Ann Arbor4
PURPOSE: To determine whether CTsigns ofpulmonary hypertensionpredict treatment response to sildenafilin idiopathic pulmonary fibrosis (IPF).
MATERIALS AND METHODS: In the Sildenafil Trial of Exercise Performance in IPF, individuals were randomized to treatment with oral sildenafil or placebo for 12 weeks. The primary outcome was improvement in 6-minute walk distance (6MWD) after treatment. Diameters of main pulmonary trunk (PT), left pulmonary artery (LPA), right pulmonary artery (RPA), and ascending aorta (AA) were measured on baseline CT¡¯s of 170 participants. To evaluate treatment effect, we compared those with values above and below the median for each measurement. A general linear model estimated 12 week change in 6MWD as a function of CT-derived indices for pulmonary hypertension, sildenafil treatment, and the interaction between CT indices and sildenafil, adjusted for age, height, sex, race and visually estimated severity of IPF on CT.
RESULTS: Median (25th, 75th percentile) values (in cm) for PT, LPA, RPA, AA were 3.27 (2.98, 3.51), 2.64 (2.38, 2.84), 2.71 (2.46, 2.91), and 3.56 (3.34, 3.79), respectively. Median PT/AA ratio was 0.92 (0.84, 0.98). The individuals were divided by PT/AA ratio into 2 groups: > 0.92, and < 0.92. Subjects with PT/AA ratio > 0.92 and treated with sildenafil showed improvement in 6MWD (mean 50.6 m) as compared with placebo treatment (95% CI: 5.8, 95.3; p=0.027). A significant sildenafil effect was not observed when PT/AA ratio was ¡Â 0.92.
CONCLUSION: In this population of subjects with moderate or advanced IPF, pulmonary artery diameters were generally above the normal range. PT/AA ratio may predict treatment response to sildenafil in patients with IPF.
¨Ï Korean Society of Radiology. All Rights Reserved.